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ABSTRACT  61 
Background: Despite increasing international interest, there is a lack of evidence about the most 62 
efficient, effective and acceptable ways to implement patient and public involvement (PPI) in clinical 63 
trials. 64 
Objective: To identify the priorities of UK PPI stakeholders for methodological research to help 65 
resolve uncertainties about PPI in clinical trials. 66 
Design: A modified Delphi process including a two round online survey and a stakeholder consensus 67 
meeting.  68 
Participants: We used snowball sampling to identify and invite UK PPI stakeholders to take part in 69 
the online Delphi. In total, 237 people registered of whom 219 (92%) completed the first round. 187 70 
of 219 (85%) completed the second; 25 stakeholders attended the consensus meeting.  71 
Results: Round 1 of the survey comprised 36 topics; 42 topics were considered in round 2 and at 72 
the consensus meeting.The number and range of topics considered by 70% plus of meeting 73 
participants to be critically important indicates the high level of uncertainty and lack of evidence to 74 
inform PPI in clinical trials. 96% of meeting participants rated the top three topics as equally 75 
important. These were: developing strong and productive working relationships between 76 
researchers and PPI contributors; exploring PPI practices in selecting trial outcomes of importance to 77 
patients; and a systematic review of PPI activity to improve the accessibility and usefulness of trial 78 
information (e.g. participant information sheets) for participants.  79 
Conclusions: The prioritised methodological research topics indicate important areas of uncertainty 80 
about PPI in trials. Addressing these uncertainties will be critical to enhancing PPI. Our findings 81 
should be used in the planning and funding of PPI in clinical trials to help focus research efforts and 82 
minimise waste.  83 
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Priorities for methodological research on patient and public involvement in clinical trials: 85 
a modified Delphi process 86 
 87 
INTRODUCTION 88 
Growing  awareness of the importance of patient centeredness in research1,2 has influenced the 89 
establishment of Patient-Centred Outcomes Research Institute (PCORI) in the United States, the 90 
National Institute for Health Research (NIHR) INVOLVE organisation in the United Kingdom (UK) and 91 
similar bodies elsewhere. These organisations have been at the vanguard of international efforts to 92 
involve patients as research partners, alongside researchers, to set research agendas, design studies 93 
and decide what outcomes should be measured.3,4 The emphasis on patient centeredness in 94 
research stems from a belief that involving patients in decisions about how studies are designed and 95 
conducted improves research, making it more relevant to end users 3,5-7 and reducing waste.8,9 96 
Patient involvement is also believed important for moral reasons, based on the principle that the 97 
people whose lives are most affected by research should have a say. In the UK patient involvement is 98 
known as Patient and Public Involvement (PPI).5,10 In clinical trials, PPI tends to involve a small 99 
number of patients or members of the public (known as PPI contributors).11 Some PPI contributors 100 
will have direct personal experience of the condition being investigated, whilst others bring general 101 
experience of being a patient or service user. A key consideration is that PPI contributors are in a 102 
position to offer a distinctive perspective to researchers or clinicians. Many UK funders require 103 
researchers seeking funding to provide evidence of how PPI will inform their studies.12-14 104 
Despite the international emphasis on PPI in the UK and internationally, there are uncertainties 105 
about how best to implement it,15 about the purpose of PPI and whether it actually does improve 106 
research.10,12,15,16 Concerns have been raised about tokenism and resourcing in PPI, about the 107 
difficulty of ensuring diversity and avoiding professionalization among PPI contributors,10,17,18 108 
complexities with researchers and patients sharing power,19 and inadequacies in training and 109 
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support for both PPI contributors and researchers.20 Problems with the conceptualisation and 110 
meaningful assessment and measurement of PPI have also been identified.21  111 
Each of these concerns points to different priorities for methodological research on PPI. Reviews of 112 
PPI in research and other contexts public involvement similarly identify many topics for future 113 
research.4,21-24 Although not all reviews focus specifically on clinical trials, trials are regarded as 114 
particularly likely to benefit from PPI20,25 by helping to address the many methodological issues that 115 
arise within trials.5 Most of these reviews of PPI echo similar concerns to those identified in the 116 
above paragraph, pointing to the need for: agreed tools for measuring PPI and its impact across the 117 
different phases of research,15,24,26,27 for investigations of how best to support PPI6,23,28 and for 118 
optimal models of implementing PPI.29,30 However, many of these topics have been identified by PPI 119 
researchers and it is unclear whether these priorities are shared by the wider community of trialists 120 
and PPI stakeholders. Given the diversity of stakeholders involved in PPI, there is considerable 121 
potential for divergence in the prioritisation of topics to investigate, and therefore for dilution of 122 
research efforts in investigating how to improve PPI in research.  123 
In the METHODs for Patient and Public Involvement In Clinical TriAls (METHODICAL study) we 124 
conducted a modified Delphi process to identify the priorities of a broad range of PPI stakeholders 125 
for methodological research to resolve uncertainties about PPI in clinical trials, as well as to help 126 
improve to the design of future PPI research and avoid unnecessary duplication of research effort.  127 
 128 
METHODS 129 
Delphis processes are used in health and social science research as a means of involving participants 130 
with relevant experience, via  in a multi staged study, to achieve consensus on a given topic.16,31,32 131 
This involves conducting sequential anonymous surveys to collect, collate and present results back 132 
to the group. To help achieve consensus, participants can view and revise their own responses in 133 
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light of group responses.32 The process can be modified to include opportunities for feedback or a 134 
consensus meeting so that participants can discuss their views.33,34  We used a modified Delphi, 135 
comprising a literature review to identify topics for research on PPI, followed by a two round online 136 
survey and stakeholder consensus meeting. 137 
We established a study team of 17 PPI stakeholders from across the UK to oversee the METHODICAL 138 
project, including: four PPI Coordinators, eight PPI researchers, one PPI planner, two PPI 139 
contributors, one non lay reviewer and one lay reviewer. Seven members of the team had secondary 140 
PPI related roles.  141 
Patient involvement 142 
Patient involvement is central to the aims and purpose of this study. Our study team included three 143 
patient partners who were involved in all aspects of study design and conduct, including 144 
development of protocol, pilot topics and accompanying text, survey recruitment, interpretation of 145 
study findings and review of this manuscript. Approximately half of the consensus meeting places 146 
were allocated to patients. We will send study participants a summary of the patient friendly copy of 147 
the study study findings. The summary A copy of the findings will also be placed on the study 148 
website and promoted through social media platforms used by patients. 149 
Recruitment  150 
To help maximise the utility of our findings we aimed to include all key paid and unpaid roles of 151 
people who co-ordinate, support and contribute to PPI in trials. Individuals were eligible to 152 
participate in the Delphi process if they had at least 12 months͛ experience of PPI in clinical trials. 153 
Study team members did not participate in the survey. As definitions of roles in PPI vary, to inform 154 
team identified seven stakeholder groups to inform recruitment,  In consultatingon with our PPI 155 
to we selected terminology to help define each group (Table 1). A free text field was included at 156 
participants could elaborate on their role/s and self-identify their role if they felt this was not 157 
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included in the list. The study team agreed that for the feedback of results in round 2 to be 158 
meaningful at the level of stakeholder group, approximately 10 participants per group would be 159 
required.  160 
[Insert Table 1 here] 161 
We used snowball sampling to identify stakeholders.35 This involved the study team using personal 162 
contacts and internet searches to develop a database of individuals, organizations and networks 163 
under each of the seven stakeholder groups. The METHODICAL researcher (AK) sent emails to the 164 
identified organisations and networksorganisations, networks and individuals (Supplementary file 165 
S1) with study information. The email included a request to invite potential survey participants by 166 
distributing the study invitation to their members or contacts list or by placing a study advert on 167 
their website or in a newsletter. Study team members also sent the email invitation to appropriate 168 
personal contacts with a request to forward the invitation to anyone with relevant experience. AK 169 
also placed an advert and link to the survey oŶ the ͚People iŶ ‘esearĐh Foruŵ͛ 170 
(www.peopleinresearch.org).  171 
Development and pilot of topics 172 
We used online search engines (e.g. google scholar and OVID (Medline ), organisational databases 173 
(e.g. INVOLVE library) and hand searches of citations within key articles to identify literature that 174 
systematically evaluated the scope and impact of PPI within health research15,20,24 to  and 175 
developedto identify a broad adevelop a list of potential methodological research topics for round 1 176 
of the Delphi. This was supplemented by a reviewing of recent publications assessing PPI specifically 177 
within clinical trials.22,23,27,36 For each topic, we developed accompanying descriptive text to help 178 
explain these. The study team, including PPI partners reviewed the list of topics and accompanying 179 
descriptions to ensure they were distinct and covered known uncertainties and challenges 180 
associated with PPI in clinical trials.  Methodological research in this context was described to 181 
participants in study information materials as: ͞methods, practices and procedures of patient and 182 
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public involvement (PPI) in clinical trials͟. We piloted the list of topics with a small group of lay (n=2) 183 
and non-lay (n=3) PPI stakeholders to check clarity and understanding and then refined the list of 184 
topics and descriptive text. (Figure1) 185 
[Insert Figure 1. Overview of the Delphi process] 186 
 187 
Online survey 188 
The online Delphi was conducted between November 2015 and March 2016. Round one was open 189 
for approximately 5 weeks and round two for 4.5 weeks. 190 
In round 1, stakeholders registered for the study by indicating their name, email address, which of 191 
the seven stakeholder groups they had the most experience in, years length of PPI experience (in 192 
years), consent to participate, interest in attending the consensus meeting and interest in receiving a 193 
copy of the published findings. We assigned each registered user a unique identifier to ensure 194 
anonymity and enable linking of scores between rounds. Participants then scored the importance of 195 
each of research topic using a scale of 1-9, with scores 1-3 being not critical or low importance, 4-6 196 
important but not critical and 7-9 of critical importance.37 Selecting a score of 10 indicated an 197 
abstention from scoring an individual topic. Participants were also invited to suggest additional 198 
topics to be added to round 2. Participants who registered but did not start attempt to complete the 199 
survey, or partially completed round 1 questions, were excluded from the analysis and not invited 200 
for round 2. Partial responders were also excluded, as it is unclear whether their responses were 201 
their final responses. The study team reviewed additional topics suggested by participants in round 1 202 
for inclusion in round 2.  203 
In round 2 we showed participants bar charts summarising the distribution of the percentage of 204 
scores 1-9 for each topic from each stakeholder group. We then invited participants to revise or 205 
keep their own score from the previous round. The email invitation for round 2 indicated that 206 
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responses received within 10 or 17 days would be entered into prize draws for a £50 voucher or a 207 
£30 voucher respectively. AK sent email reminders periodically to non responders.  208 
Consensus meeting 209 
We allocated thirty places to equal numbers of lay and non-lay stakeholders with broad 210 
representation across the seven stakeholder groups (Table 2). The METHODICAL study team were 211 
invited to attend and participate in the consensus meeting.  Three study team members helped to 212 
facilitate the meeting and did not take part. Ten other study team members registered to attend as 213 
participating stakeholders and were allocated either lay or non-lay places based on their primary PPI 214 
roles. We invited survey participants at random within their stakeholder group. Only survey 215 
participants who completed both rounds of the survey and who registered their interest in attending 216 
the consensus meeting were eligible to attend.  217 
AK emailed each registered attendee a copy of the agenda and their scores from round 2 one week 218 
before the meeting. PW, a member of the METHODICAL team, facilitated the meeting due to her 219 
previous experience  in this rolefacilitating consensus meetings. Team members KW and AK began 220 
the meeting with a short study overview.  AK presented the results from round 2 sequentially and in 221 
the same order as presented in the online survey. Each topic and accompanying description was 222 
presented together with bar charts showing how each stakeholder group had scored each topic. We 223 
provided attendees with paper copies of their individual scores and the level of consensus achieved 224 
within stakeholder groups during round 2 (Supplementary file S4). PW began by asking attendees if 225 
any clarification of the topic was required. Comments and discussion were then encouraged before 226 
PW asked attendees to consider whether or not the topic should be prioritised for future research. 227 
Where more than 70% of round 2 participants in any one stakeholder group had indicated a topic 228 
was of high importance (scored it 7-9), we invited attendees to raise opposing arguments. A similar 229 
approach was followed for those topics where less than 50% of round 2 participants in any one 230 
group had indicated a topic to be of less importance (scored it 1-3), with views requested if a 231 
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participant felt strongly that a topic should be considered important. PW encouraged a fuller 232 
discussion where the online survey results indicated mixed views on a topic. Following discussion of 233 
each topic an anonymous vote was undertaken using a hand held voting device (Turning Point 234 
software, version 5). Meeting attendees could abstain from voting for an individual topic by 235 
selecting a score of 10. This process was repeated until all topics were discussed and voted on. 236 
AK circulated a written report to meeting attendees seven weeks after the meeting, which included 237 
notes from meeting discussions and any changes made to the topic description text.  238 
Statistical Analysis 239 
We pre-defined consensus as 70% or more participants scoring 7 to 9 and less than 15% participants 240 
scoring 1 to 3 on a particular topic.38,39 All statistical analysis was performed in R version 3.2. We 241 
ranked final research topics from the METHODICAL consensus meeting according to the percentage 242 
of participants scoring a research topic as critically important (scores 7-9) and then by ascending 243 
order of the percentage of scores 1- 3.  244 
RESULTS 245 
Online Survey 246 
Response rates by stakeholder group for round 1 and 2 are shown in Table 2. Of the 237 people who 247 
registered for the survey, 219 (92%) completed round 1. Twelve individuals registered but did not 248 
start the survey and six provided partial responses (Figure 1).  All eighteen individuals were excluded 249 
from the analysis. Of the 219 who completed round 1, 187 (85%) completed round 2 and were 250 
included in the analysis. Of the remaining 32, one withdrew from round 2 of the survey, two died, 251 
two partially completed round 2, and 27 did not complete any part. Completion rates by stakeholder 252 
group for round 1 and 2 are shown in Table 2. Round 1 of the survey comprised 36 methodological 253 
research topics (Supplementary file S2). The study team reviewed 81 additional research topics 254 
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suggested by survey participants. Of these, we agreed that 46 suggestions were within the scope of 255 
existing topics, although we added additional examples to seven existing topics or descriptors to 256 
improve their clarity. Twenty eight suggestions contributed to the development of six new topics 257 
which were added to round 2.  The remaining seven suggestions related to trial participants not PPI 258 
and were therefore considered to be out of scope. However, these led to the inclusion of a new 259 
topic aimed at exploring the defiŶitioŶ of PPI aŶd people͛s uŶderstaŶdiŶg of it. Round 2 of the survey 260 
comprised of 42 methodological research topics, including the six new topics created from 261 
participant suggestions. 262 
At the end of round 2 wWe reviewed results against the definition of consensus agreed at the 263 
beginning of the study. At the end of round 2 there was no consensus across all stakeholder groups 264 
as to which research topics were of critical importance. Only three topics achieved consensus across 265 
six of the seven groups (Supplementary file S4).  266 
Consensus Meeting 267 
Of the 30 people registered, 25 people attended the meeting and were eligible to vote (Table 2).  268 
Seventeen were survey participants and eight members of the METHODICAL study team. Twelve 269 
(48%) attendees were lay and 13 (52%) were non-lay. Although no attendees identified PPI advisor 270 
as the stakeholder group that they most identified with, at least two had PPI advisor roles; all 271 
stakeholder groups were therefore represented at the meeting.  272 
[Insert Table 2 here] 273 
All 42 topics were discussed and voting was undertaken on all except two, topics 38 and 39. 274 
Following discussion attendees concluded that topic 38 (methods to measure PPI impact) should be 275 
subsumed within topic 37 (core outcomes to evaluate PPI), while topic 39 (characteristics of PPI 276 
which lead to a successful trial) was considered to be too broad. We made changes to three topic 277 
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titles and nine descriptive help texts after group discussion in order to clarify the topic before voting 278 
(Supplementary file S2). 279 
The supplementary file S3 provides the final ranked list of all research topics. Sixteen topics achieved 280 
consensus with greater than 70% of participants scoring them 7-9 and less than 15% scoring them 1-281 
3.  As shown in Table 3 the top ten prioritised research topics were varied, covering PPI processes, 282 
resources, practices and relationships between stakeholder groups. Three topics shared joint ͚first 283 
plaĐe͛ with 96% of meeting attendees rating each as critically important: developing strong and 284 
productive working relationship between researchers and PPI contributors; PPI practices in selecting 285 
trial outcomes of importance to patients; and a systematic review of PPI activity in improving the 286 
accessibility and usefulness of trial information (e.g. leaflets and information sheets) for clinical trial 287 
participants.  288 
[Insert Table 3 Here] 289 
As discussed previously, an additional topic, regarding the defiŶitioŶ of PPI aŶd people͛s 290 
understanding of it, was added to round 2. Attendees gave low ratings for this topic, commenting 291 
that improved communication about the definition of PPI was needed within the trials community 292 
rather than more research on this definition. Of the six topics suggested by survey participants, only 293 
one (Topic 13: Exploring the role of PPI in the early stages of testing of new treatments [e.g. Phase 1 294 
and Phase 2 trials]) reached consensus among meeting attendees (Supplementary file S3). 295 
 296 
DISCUSSION  297 
Through a consensus building process we have identified priority topics for methodological research 298 
to inform PPI in clinical trials. The prioritised research topics were varied, covering PPI processes, 299 
resources, practices and relationships between stakeholder groups. The number and range of topics 300 
considered by more than 70% of meeting participants to be critically important indicates the high 301 
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level of uncertainty and lack of evidence to inform PPI in clinical trials.2,4,23,27 Meeting attendees 302 
were virtually unanimous about the most important PPI research priorities, with the top six 303 
achieving over 92% consensus.  304 
Several of the top ten prioritised research topics address concepts that are fundamental to PPI in 305 
clinical trials, such as productive working relationships, resources and how to adapt PPI models to 306 
avoid a one size fits all approach.30 Previous studies of PPI in clinical trials, have particularly 307 
highlighted the importance of productive working relationships in creating the sort of environment 308 
to enable contributors to make a difference to research,27,40,41 whilst Barber et al, recommended 309 
considering PPI as a dynamic partnership rather than a procedural activity.17 During the consensus 310 
meeting many stakeholders shared examples of poor relationships between PPI contributors and 311 
researchers, also reflecting the high priority placed on the development of strong and productive 312 
partnerships between researchers and PPI contributors.   313 
Whilst online resources such as INVOLVE provide costing tools for planning PPI, publications are 314 
poor at reporting the true costs.42 Topic 9 (resources needed for PPI activity), highlights uncertainties 315 
around PPI costs and points to concerns regarding the adequacy of funding to meet these costs. 316 
Research is therefore needed to help identify what level of resource is required for the 317 
implementation of PPI to ensure PPI plans for such involvement in trials are realistic and adequately 318 
supported. Whilst work is being undertaken to develop frameworks and guidelines to guide PPI 319 
practice in research,43-45 PPI plans and activities often vary according to context.23 Two of the top ten 320 
prioritised topics (Topics 4 and 2) point to concerns about current models of PPI,29,30 highlighting the 321 
need for research to explorelook at how to adaptations of PPI to the needs of particular trials, as 322 
well as methods to capture wider patient and public perspectives. For example, concerns were 323 
raised about current models of PPI being tokenistic, due to often small numbers (one or two) PPI 324 
contributors working on each seeking to share a lay perspective on trials.10,17,18  Research is needed 325 
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to evaluate the effectiveness of different methods to increase diversity and capture wider patient or 326 
public perspectives on clinical trial designs, such as online surveys and social media.   327 
Some of the top ten topics focus on the impact of PPI and particularly the need to review PPI in 328 
specific trial processes, such as: the development of trial information for patients; recruitment and 329 
retention of patients; choice and measurement of outcomes; and the dissemination of results.  Two 330 
of these (Topic 28, strategies to recruit and retain patients, and Topic 29, the selection of trial 331 
outcomes)  align with existing methodological research agendas for clinical trials.38 Conceptually, PPI 332 
should have a substantial role in addressing these issues. However, our results demonstrate that 333 
further work is needed to map and formally evaluate current PPI practices to help make these more 334 
relevant to patients end users, which in this context are the patients who are invited to participate in 335 
trials, 3,5-7 and help to reduce research waste by targeting resources more effectivelyreduce waste.8,9  336 
For example, it is common to involve patients in developing information materials for prospective 337 
trial participants43 yet it is unclear whether or how this input increases participation rates or 338 
improves patient experience of research.20 A systematic review of PPI activity in the development of 339 
information materials for prospective trial participants (Topic 31) may provide evidence of the 340 
impact of such work, as well as inform future PPI in this important aspect of trial development.  341 
During the consensus meeting some prioritised topics were revised to define a research method to 342 
be used to explore that particular topic, such as Topic 31: A systematic review of PPI activity in 343 
improving accessibility and usefulness of trial leaflets and information sheets for clinical trial 344 
participants͛, whilst others, such as Topic 20 ͚Developing strong and productive working 345 
relationships between researchers and PPI contributors͛ are more wide-ranging general and relate to 346 
challenges in PPI. Such widerbroader topics may contain multiple components, and further 347 
consideration will be needed to develop these topics into formal research questions and to identify 348 
the most appropriate research methods for addressing these questions.32  349 
 350 
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Our study had several strengths. The METHODICAL team included representation of all stakeholder 351 
groups including lay and non-lay members, who oversaw all stages of the project, including the 352 
recruitment strategy. The survey sample size was also relatively large compared to other Delphi 353 
studies and the attrition rate was low., with those taking part in round 1 likely to complete round 2. 354 
Comparison of round one mean scores between those who did and did not complete round two 355 
indicate that our study was not affected by attrition bias (Supplementary file S5).  356 
We took several a number of steps to help ensure that all stakeholder groups were represented at 357 
every stage of the Delphi and that all groups and individuals felt able to contribute freely. We 358 
sampled stakeholders purposively for the survey stage. For the consensus meeting a random 359 
selection of participants within groups ensured balance and fairness in the allocation places for lay 360 
and non-lay stakeholders across all seven of stakeholder groups. Care was taken in the facilitation of 361 
the meeting to ensure that all attendees had an equal opportunity to contribute to discussions.  362 
High and low priority topics identified in our study are cited in international literature on public and 363 
patient involvement in research46-48. However, further research is required to explore the level of 364 
priority given to these topics in international settings. 365 
The study also had some limitations. As the potential sample was large and diverse we were unable 366 
to fully define the sampling frame and used snowball sampling to try to make sure all stakeholder 367 
groups were included in the sample. As a result, our study was subject to self-selection bias among 368 
those who registered for the study. Some study team members participated in the consensus 369 
meeting, which meant that a sub-set of attendees were not independent from the project. We 370 
reasoned that they would bring valuable experience and expertise to the discussion 49 and therefore 371 
included them in the meeting. To promote transparency, at the beginning of the meeting all 372 
attendees introduced themselves and stated whether they took part in the survey, or whether they 373 
were a member of the study team. Care was taken in the facilitation of the meeting to ensure that 374 
all attendees had an equal opportunity to contribute to discussions.  To help attendees feel free to 375 
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vote as they wished during the meeting, voting was anonymous. However, as we did not track 376 
individual votes during the meeting, we are unable to present consensus meeting voting data by 377 
stakeholder group, or assess how individual scores differed from the online survey.  378 
The Delphis process is are dependent upon the participants having time to commit to the process to 379 
until it is completione.50 To reduce the potential burden on participants and minimise attrition bias 380 
we choose a two round, rather than a three or four round survey.33,51,52 While consensus was not 381 
achieved in the two round survey, it was achieved at the meeting, which highlights the value of face 382 
to face discussion and collective deliberation in reaching consensus.  383 
Rather than beginning with an open question about possible topics and inviting suggestions from 384 
participants, the list of topics presented in round 1 was derived from the existing literature.53 385 
However, we also invited participants to suggest additional topics in round 1. Despite a large 386 
number of suggested topics, relatively few new topics were suggested. Indeed, the majority of topics 387 
put forward by participants were already encompassed by existing topics. This perhaps indicatesing 388 
that our approach of presenting a list of topics in round 1 was an appropriate way of conducting a 389 
methodological research priority setting exercise in a context where not all stakeholders would be 390 
familiar with the concept of methodological research and might struggle to identify priorities 391 
without some examples as prompts.  392 
 393 
CONCLUSIONS 394 
In conclusion, the prioritised methodological research topics identified by the Delphi process 395 
highlight key uncertainties about PPI in trials. Addressing these uncertainties will be critical to 396 
enhancing PPI.  Our findings should be used by those involved in planning and funding of PPI in 397 
clinical trials to help focus research efforts and minimise waste.  398 
  399 
 400 
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Table 1: Stakeholder Groups for the Delphi process 
 
Stakeholder Group Definition and examples 
PPI Contributors Patient representatives, research partners in clinical trials 
Lay Reviewers Members of the public sitting on clinical trial funding boards or 
Research Ethics Committees (RECs) 
PPI Coordinators Roles within a Clinical Trial Unit (CTU) or research network to 
coordinate PPI activity and PPI contributors and research partners in 
trials 
PPI Advisors Roles offering advice on how to design and deliver PPI activity within 
trials. This predominantly includes member of the National Institute 
for Health Research (NIHR) Research Design Service (RDS) 
PPI Planners Chief Investigators, trial managers and other researchers/staff who 
plan or oversee PPI in individual trials 
PPI Researchers People who conduct research into PPI in clinical trials and authors of 
PPI guidance documents 
Non-lay Reviewers Professional members of clinical trial funding boards or Research 
Ethics Committees (RECs) 
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Table 2: Stakeholder representation within the survey and at the meeting  
Stakeholder 
group 
No. of people (% of stakeholders from previous rounda) 
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Lay reviewers 51 48 94% 39 81% 7 18% 6 86% 
PPI contributors 37 36 97% 27 75% 8 30% 6 75% 
Total Lay 88 84 95% 66 79% 15 23% 12 80% 
          
Non-lay 
reviewers 
40 38 95% 33 87% 3 9% 3 100% 
PPI Planners  53 47 89% 39 83% 4 10% 4 100% 
PPI advisors 13 12 92% 12 100% 1 8% 0
b 0% 
PPI coordinators 26 25 96% 25 100% 4 16% 4 100% 
PPI researchers 17 13 76% 12 92% 3 25% 2 67% 
Total Non-lay 149 135 91% 121 90% 15 12% 13 87% 
          
TOTAL 237 219 92% 187 85% 30 16% 25 83% 
Legend: a For example the percentage of Lay reviewers who registered and completed round 1 (94%) 
is the number who completed (n=48) divided by the number registered (n=51) bAt least two people 
with secondary roles of PPI advisor were present at the consensus meeting.    
Stakeholder 
group 
No. Registered No. who 
completed 
round 1 
(% of 
registered a) 
No. who 
completed 
round 2 
(% of round 1) 
No. who 
accepted the 
meeting 
invitation 
(% of round 2 
completers) 
No. of meeting 
attendees 
(% of those 
invited) 
Lay reviewers 51 48 (94%) 39 (81%) 7 (18%) 6 (86%) 
PPI contributors 37 36 (97%) 27 (75%)  8 (30%) 6 (75%) 
Total Lay 88 84 (95%) 66 (79%) 15 (23%) 12 (80%) 
      
Non-lay 
reviewers 
40 38 (95%) 33 (87%) 3 (9%) 3 (100%) 
PPI Planners  53 47 (89%) 39 (83%) 4 (10%) 4 (100%) 
PPI advisors 13 12 (92%) 12 (100%) 1 (8%) 0
b (0%) 
PPI coordinators 26 25 (96%) 25 (100%) 4 (16%) 4 (100%) 
PPI researchers 17 13 (76%) 12 (92%) 3 (25%) 2 (67%) 
Total Non-lay 149 135 (91%) 121 (90%) 15 (12%) 13 (87%) 
      
TOTAL 237 219 (92%) 187 (85%) 30 (16%) 25 (83%) 
Commented [KA14]: I wonder if this is a clearer way to present 
the table given the formatting requirements? 
26 
 
 
Table 3: Top 10 Methodological priorities for PPI in clinical trials 
Ranking Topic 
No. 
Topic Title Help text % of meeting 
scores 
7-9 1-3 
1 TOPIC 
20 
Developing strong and 
productive working 
relationships between 
researchers and PPI 
contributors 
Research on what defines and enables a good working 
relationship between researchers on a trial team, trial 
committee (e.g. trial steering committee or ethics committee) or 
funding panels and PPI contributors? Exploring the impact of role 
descriptions, selection criteria, clear expectations, language, 
communication and handling conflict. 
96% 0% 
1 TOPIC 
29 
PPI practices in 
selecting trial 
outcomes of 
importance to patients 
A review of PPI practices that influence the primary outcomes 
within clinical trials e.g. seizure control at 6 months, time to 
healing. How often are these outcomes that are of importancet 
to patients, and what role did PPI play in the decision making 
process? 
96% 0% 
1 TOPIC 
31 
A systematic review of 
PPI activity in 
improving the 
accessibility and 
usefulness of trial 
leaflets and 
information sheets for 
clinical trial 
participants 
Patient/public contributors often help trial teams to design and 
produce information sheets. An assessment of existing research 
to evidence how PPI impacts patients understanding and 
acceptability of PIS within trials? How do PPI contributors write 
or review Patient Information Sheets? How often are they given 
guidance for this? Do trial teams listen to the advice of PPI 
contributors, how often are their changes adopted? 
96% 0% 
4 TOPIC 
4 
Adapting PPI to the 
particular needs of 
individual clinical trials 
Research on how to tailor PPI plans to take into account key 
design features or specific patient groups e.g. critically ill patients 
or children, including how the needs of clinical trials for PPI 
might change over the life of a trial., For example would a 
specific type of trial benefit from the use of patient panels rather 
than having one or two lay members on the trial steering 
committee? 
92% 0% 
4 TOPIC 
9 
The resources needed 
for PPI activity 
including time and 
money. 
What are the resource implications for undertaking PPI? Do 
resource limitations impact upon PPI activity? What is spent on 
PPI activity for grant applications? How much budget is allocated 
within trials, what does it actually cost and is it possible to 
quantify the benefits in monetary terms? Evaluating current 
payment systems upon Involvement of PPI contributors at all 
stages of a trial. 
92% 0% 
4 TOPIC 
28 
PPI practices to 
address the challenges 
of recruiting and 
retaining participants 
(e.g. patients) in 
clinical trials 
Exploring the effectiveness of PPI practices to improve 
recruitment of patient participants (i.e. the people taking part as 
͚suďjeĐts͛ iŶ ĐliŶiĐal trialsͿ, or help keep patieŶts ǁithiŶ a trial. 
92% 0% 
7 TOPIC 
30 
PPI practices in 
selecting how to 
measure trial 
outcomes 
A review of how PPI is used to decide on how outcomes are 
measured. For example how does PPI contribute to deciding 
whether a trial should collect data from patients using a weekly 
diary or a monthly questionnaire? 
88% 0% 
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8 TOPIC 
35 
How is PPI involved in 
the dissemination of 
results and assessment 
of effectiveness? 
A review of how PPI contributors are involved in writing lay 
reports for patient organisations or trial participants and 
presenting findings at conferences. Does involving PPI 
contributors impact on the effectiveness of dissemination? How 
often are funds available for this PPI work? 
84% 0% 
9 TOPIC 
22 
How do PPI 
contributors achieve 
and maintain an 
authentic patient 
perspective? 
How does personal experience along with social demographics 
shape the perspective and input of a PPI contributor? Do PPI 
ĐoŶtriďutors ďeĐoŵe ͞professioŶalised͟ ;i.e. ŵore like 
researchers) over time? What helps to avoid this and keep them 
͞iŶ touĐh͟ ǁith the autheŶtic patient perspective? Do PPI 
contributors collect feedback from members of the public/ other 
patients to help them in their role? If so what methods do they 
use and are they effective? 
84% 12% 
10 TOPIC 
2 
Effectiveness of 
different methods to 
capture wider patient 
or public perspectives 
on clinical trial designs 
e.g. surveys, social 
media 
PPI traditionally involves one person or small numbers of 
patieŶts or puďliĐ represeŶtatiǀes seekiŶg to share a ͚laǇ 
perspeĐtiǀe͛ oŶ trials. This researĐh ǁould look at ways to 
involve larger numbers of people in PPI within clinical trials. 
80% 0% 
10 TOPIC 
33 
What is the impact of 
PPI activity on the 
experience of patients 
who participate in a 
clinical trial? 
Assessing the impact of PPI activity on a patients͛ experience of 
trial participation, including their experience of consent, 
treatment, follow up and communication of the results. 
80% 0% 
 
